Cancer — The Harmonism Protocol

Part of the Wheel of Health. See also: Inflammation & Chronic Disease, Purification, Biggest Levers, Monitor.

This protocol addresses cancer in both registers the terrain view demands: prevention — building a body cancer cannot easily inhabit — and treatment — the metabolic, immunological, enzymatic, oxidative, pharmacological, and biophysical means by which an established cancer is fought on its own ground, outside the captured paradigm of cytotoxic poisoning. What follows moves from the terrain to the disease: first the Harmonism position and the metabolic theory, then the six pillars that build a cancer-resistant body, then — in Part II — the active treatment protocol. The two halves are one architecture. The same terrain that prevents cancer is the ground on which every treatment succeeds or fails.

Harmonism Position on Cancer

Cancer is not random. The dominant narrative — cancer as genetic lottery, as pure bad luck in cell division — captures one dimension while obscuring the deeper, more actionable truth: cancer is fundamentally a disease of terrain. Mutations occur constantly in every living body. The relevant question is not whether mutations happen but whether the body’s surveillance and repair systems can contain them. When the terrain is degraded — when inflammation becomes chronic, insulin remains elevated, the immune system atrophies, oxygen delivery fails, and detoxification systems are overwhelmed — mutations that would normally be recognized and eliminated are instead permitted to establish, proliferate, and metastasize. The cell becomes cancerous not merely because of its mutations but because the body has lost the capacity to defend against them.

This reframing carries enormous practical weight. If cancer is purely genetic — the bad-luck narrative — then prevention collapses to screening and, for high-risk individuals, prophylactic surgery. The individual’s actions mean little. If cancer is primarily a disease of terrain, with genetics as one risk modifier among many, then prevention becomes something the sovereign practitioner can actively pursue through the metabolic, immunological, and lifestyle interventions that the Wheel of Health structures.

Harmonism does not deny genetic risk — BRCA mutations, Lynch syndrome, Li-Fraumeni syndrome genuinely increase susceptibility. But it holds that terrain determines manifestation. A BRCA carrier with optimal metabolic health, robust immune surveillance, low chronic inflammation, excellent sleep, and minimal toxic burden inhabits a fundamentally different risk landscape than a BRCA carrier with metabolic syndrome, fragmented sleep, and high inflammatory markers. Genetics loads the gun; terrain pulls the trigger. The protocol below addresses terrain. Genetic risk management (screening, specialist consultation, potential prophylactic intervention) is a complementary and sometimes essential track, but not the whole story.

The Metabolic Theory of Cancer

Conventional oncology rests on the somatic mutation theory (SMT): cancer arises from accumulated DNA mutations that progressively transform a normal cell into a malignant one. This theory, dominant for decades, structures the approach to cancer: genetic testing, targeted molecular therapies, and chemotherapy.

A growing and increasingly rigorous body of evidence articulates a complementary perspective: the metabolic theory of cancer, most precisely formulated by Thomas Seyfried (building on Otto Warburg’s foundational observations from the 1930s). The core proposition is direct: cancer is fundamentally a metabolic disease characterized by damaged mitochondria. Cancer cells lose the capacity for efficient oxidative phosphorylation — the normal, oxygen-dependent energy pathway — and become dependent on fermentation: the glycolytic pathway that burns glucose and glutamine for fuel regardless of oxygen availability. This is the Warburg effect.

The practical implications cascade through every aspect of prevention:

Glucose and insulin are fuel for cancer. If cancer cells are metabolically dependent on glucose, then chronic hyperglycemia and hyperinsulinemia create a permissive metabolic environment. Insulin itself functions as a growth factor through IGF-1 signaling — promoting cell proliferation, inhibiting apoptosis, and directly fueling the cancer progression pipeline. The connection between metabolic syndrome and cancer risk is not speculative but measurable.

Ketosis creates metabolic asymmetry. When the body shifts from glucose to ketone metabolism — through fasting, ketogenic diet, or sustained movement — healthy cells with functional mitochondria adapt readily. Cancer cells cannot efficiently utilize ketones. This creates a metabolic differential that the immune system can exploit. Periodic fasting and metabolic flexibility are therefore not merely weight management tools but cancer prevention strategies at the cellular level.

Mitochondrial integrity is cancer prevention. Everything that damages mitochondria — chronic oxidative stress, environmental toxins, micronutrient depletion (CoQ10, magnesium, B vitamins), chronic inflammation — increases the probability of metabolic collapse toward fermentation. Conversely, everything that preserves mitochondrial function — consistent movement, intermittent fasting, cold exposure, micronutrient sufficiency — is directly cancer-protective.

Harmonism does not choose between mutation theory and metabolic theory — it recognizes their interdependence. Damaged mitochondria create genomic instability; accumulated mutations further impair mitochondrial function. The practical convergence is clear: the same interventions that restore the metabolic terrain also reduce mutation frequency and enhance repair capacity. The choice between two theories dissolves when you address the terrain itself.

The Six Pillars of Cancer Prevention

1. Metabolic Health — Starve the Terrain

The single most consequential cancer prevention strategy is metabolic health: normal fasting glucose, low fasting insulin, low visceral fat, and intact insulin sensitivity. This is not a cancer-specific intervention — it is the same metabolic foundation that prevents diabetes, cardiovascular disease, and neurodegeneration. Cancer prevention is metabolic prevention viewed through a specific lens.

Key targets:

Fasting insulin below 5 µIU/mL. This is the gold standard marker for metabolic cancer risk. Elevated insulin drives IGF-1, promotes cell proliferation, inhibits apoptosis, and creates a growth-permissive environment. Achieving this requires the dietary and movement interventions described in The First 90 Days and Nutrition.

Fasting glucose 70–85 mg/dL, HbA1c below 5.3%. Chronic hyperglycemia fuels the Warburg effect directly.

Visceral fat minimized. DEXA scan or waist-to-hip ratio as proxies. Visceral fat is not merely a marker of metabolic dysfunction — it actively produces inflammatory cytokines, aromatase (converting testosterone to estrogen, driving hormone-sensitive cancers), and adipokines that promote angiogenesis (new blood vessel formation that tumors need to grow).

Periodic fasting. Time-restricted eating (daily 16:8 or 14:10) as baseline. Quarterly extended fasts (24–72 hours) for autophagy activation. Autophagy — the cellular recycling process triggered by nutrient deprivation — clears damaged mitochondria (mitophagy), misfolded proteins, and pre-cancerous cells. Valter Longo’s research on fasting-mimicking diets demonstrates measurable reduction in IGF-1, inflammatory markers, and cancer biomarkers with periodic 5-day fasting cycles.

Glucose-Ketone Index (GKI) as metabolic cancer marker. The GKI is the single most actionable metric for metabolic cancer prevention and therapeutic fasting. Calculation: blood glucose (mg/dL) ÷ 18 ÷ blood ketone level (mmol/L). Target ranges: GKI 6–9 for general metabolic health; GKI 1–3 for therapeutic cancer protocol (blood glucose 60–85 mg/dL, blood ketones 2–4 mmol/L); GKI under 1.0 for maximum metabolic pressure during supervised therapeutic fasting. A dual blood glucose/ketone meter provides the necessary data — this is Monitor applied to metabolic terrain at its most precise. Sustained GKI in the 1–3 range creates the metabolic differential that makes cancer cells vulnerable: healthy cells with functional mitochondria adapt to ketone metabolism; cancer cells dependent on fermentation cannot.

2. Anti-Inflammatory Terrain

Chronic inflammation creates the microenvironment in which cancer initiates and progresses. The full anti-inflammatory protocol is detailed in Inflammation-Chronic-Disease. The cancer-specific emphasis:

NF-κB suppression. NF-κB is the master inflammatory transcription factor, and it is constitutively activated in many cancer types. Curcumin, sulforaphane, omega-3 fatty acids, and resveratrol all modulate NF-κB signaling.

Nrf2 activation. The Nrf2 pathway controls the body’s antioxidant and detoxification response. Activating Nrf2 upregulates glutathione, SOD, and catalase — the body’s own defense against oxidative DNA damage. Sulforaphane (from broccoli sprouts) is the most potent known natural Nrf2 activator. Daily consumption of broccoli sprouts (30g) or supplementation with sulforaphane extract provides meaningful Nrf2 induction.

Resolving inflammation, not just suppressing it. The body produces specialized pro-resolving mediators (resolvins, protectins, maresins) from omega-3 fatty acids. These actively resolve inflammation rather than merely blocking the inflammatory signal. Adequate omega-3 intake (2–4g EPA/DHA daily) ensures the substrate for resolution is available.

3. Immune Surveillance — The Body’s Anti-Cancer System

The immune system identifies and destroys abnormal cells constantly — the process called immune surveillance. Natural killer (NK) cells, cytotoxic T cells, and macrophages patrol for cells displaying aberrant surface markers. Cancer only establishes itself when this surveillance fails.

What suppresses immune surveillance:

Chronic stress (cortisol suppresses NK cell activity). Sleep deprivation (a single night of restricted sleep reduces NK cell activity by up to 70%, per Matthew Walker’s research). Vitamin D deficiency (vitamin D is a potent immune modulator — low levels correlate with increased cancer risk across multiple types). Chronic inflammation (paradoxically, chronic immune activation leads to immune exhaustion, reducing the capacity for targeted anti-cancer responses). Gut dysbiosis (70–80% of immune tissue is in the gut — a compromised microbiome impairs systemic immune function).

What enhances immune surveillance:

Sleep. 7–9 hours, consistent timing. Non-negotiable. The most powerful immune-supportive intervention available.

Vitamin D. Target blood level: 50–70 ng/mL (125–175 nmol/L). Strong epidemiological evidence links higher vitamin D levels with reduced incidence of colorectal, breast, prostate, and several other cancers. Dose to blood level — typically 4,000–6,000 IU daily, tested and adjusted.

Medicinal mushrooms. Reishi (Ganoderma lucidum), turkey tail (Trametes versicolor), chaga (Inonotus obliquus), and maitake (Grifola frondosa) have demonstrated immunomodulatory effects in human research — specifically, enhancement of NK cell activity and T-cell function. The Taoist tonic herbalism tradition uses reishi as the supreme Shen tonic and immune regulator. Turkey tail (PSK/PSP polysaccharides) has been used as an adjunctive cancer therapy in Japan for decades.

Exercise. Moderate-intensity exercise acutely increases NK cell mobilization and cytotoxicity. Regular exercise creates a sustained improvement in immune surveillance. The key word is moderate — overtraining suppresses immunity.

Cold exposure. Brief cold water immersion increases circulating NK cells and other immune parameters. Hormetic stress primes the immune system.

Lymphatic circulation. The lymphatic system is the channel through which immune cells patrol and through which metastatic cells must travel to spread. Unlike blood, lymph has no central pump — it moves through muscular contraction, and particularly well through the rhythmic vertical loading of gentle bouncing. A few minutes of soft rebounding several times a day mobilizes lymphatic flow at minimal metabolic cost, supporting both surveillance and drainage without the immune-suppressing effect of overtraining.

4. Detoxification — Reduce the Carcinogen Load

Environmental carcinogens are a modifiable risk factor. The body accumulates heavy metals, persistent organic pollutants (POPs), pesticide residues, and endocrine disruptors — many of which are directly genotoxic (causing DNA damage) or epigenotoxic (altering gene expression in ways that promote cancer).

Priority carcinogens to reduce:

Heavy metals: Mercury (from dental amalgams, large predatory fish), lead (from old paint, contaminated water, some supplements), cadmium (from cigarettes, contaminated soil, some cocoa), arsenic (from rice, groundwater). Testing: a provoked heavy metal urine test (with DMSA challenge) provides the most accurate assessment of body burden. Chelation with DMSA or EDTA under practitioner guidance for significant loads. Daily mitigation: chlorella, cilantro, selenium, NAC (supports glutathione — the body’s primary heavy metal detoxifier).

Endocrine disruptors: BPA and BPS (from plastic containers, receipts, can linings), phthalates (from fragrances, soft plastics, personal care products), PFAS (from non-stick cookware, waterproof fabrics). These disrupt estrogen, testosterone, and thyroid signaling — directly relevant to hormone-sensitive cancers (breast, prostate, ovarian, endometrial). Mitigation: glass and stainless steel food storage, natural personal care products, cast iron or stainless steel cookware, water filtration.

Pesticides: Glyphosate (the most widely used herbicide globally) has been classified as a “probable human carcinogen” by the WHO’s IARC. Organophosphates and organochlorines have known endocrine-disrupting and genotoxic effects. Mitigation: organic produce for the “dirty dozen” highest-pesticide crops at minimum, broad organic diet where economically feasible.

Sauna for detox: Regular sauna use mobilizes fat-soluble toxins through sweat — a significant excretion pathway for heavy metals and POPs. The Hubbard protocol (sauna combined with niacin and exercise) was originally developed for detoxifying drug residues and has been adapted for environmental toxin clearance. 3–5 sauna sessions per week is the evidence-supported frequency. See Purification and Recovery for detailed protocols.

5. Anti-Cancer Nutrition — Specific Foods and Substances

Beyond the general anti-inflammatory framework, specific foods and compounds have demonstrated anti-cancer activity in human research:

Cruciferous vegetables — sulforaphane (from broccoli, broccoli sprouts, Brussels sprouts, kale, cauliflower) induces phase 2 detoxification enzymes, activates Nrf2, inhibits histone deacetylase (an epigenetic mechanism exploited by cancer cells), and promotes apoptosis in cancer cell lines. Broccoli sprouts contain 20–100x more sulforaphane precursor than mature broccoli.

Green tea — EGCG (epigallocatechin gallate) inhibits angiogenesis, induces apoptosis, and modulates multiple signaling pathways involved in cancer progression. 3–5 cups of high-quality green tea daily or supplemental EGCG (400–800mg).

Turmeric/curcumin — NF-κB inhibition, COX-2 inhibition, angiogenesis inhibition, apoptosis induction. Bioavailable form (phytosomal or with piperine), 500–1000mg daily.

Garlic and alliums — allicin and diallyl sulfide activate detoxification enzymes and have demonstrated anti-cancer effects in epidemiological studies (particularly colorectal and stomach cancer). Crush garlic and wait 10 minutes before cooking to allow allicin formation.

Berries — ellagic acid (raspberries, strawberries, pomegranates) and anthocyanins (blueberries, blackberries) have anti-proliferative and anti-angiogenic effects. Daily consumption.

Fermented foods — butyrate (produced by gut bacteria fermenting fiber) has direct anti-cancer effects on colonocytes. Maintaining a diverse, fiber-fed microbiome is colorectal cancer prevention.

Modified citrus pectin — binds galectin-3 (a protein involved in cancer cell adhesion and metastasis). Emerging evidence in prostate cancer specifically.

Cell-membrane fatty acids — the integrity of the cell membrane governs how readily oxygen crosses into the cell, and oxygen-starved cells are precisely the ones that drift toward fermentative, cancer-permissive metabolism. This directs attention to the parent essential fatty acids — unoxidized linoleic and alpha-linolenic acid from fresh, cold-pressed sources — as the raw material of an oxygen-permeable membrane, and away from the oxidized and industrially processed oils that degrade it. One contested corollary holds that concentrated fish-oil supplements, being highly prone to oxidation, may do net harm relative to whole-food omega-3 sources; the evidence there is genuinely mixed. The load-bearing counsel is sound on independent grounds regardless of how that dispute resolves: favor fresh whole-food fats, avoid oxidized and processed oils.

6. Screening and Genetic Risk Management

Early detection is a genuine good, and it belongs to Monitor — the center of the Wheel of Health. Knowing that cancer is present, early, while the terrain can still be turned, is real intelligence, and the sovereign practitioner wants it. But detection is not one thing, and Monitor does not accept the diagnostic apparatus wholesale. Some methods reveal what is present at little or no cost to the body. Others manufacture disease — treating lesions that would never have killed — or inflict the very harm they claim to guard against: irradiating healthy tissue, or disturbing a contained tumor in the act of sampling it. The same captured incentive structure that shapes pharmaceutical medicine shapes the diagnostic industry — a test or procedure that generates further procedures is profitable whether or not it extends a single life. So the discernment runs method by method: does this reveal lethal cancer early enough to change the outcome, and does it do so without inflicting more harm than the knowledge is worth? Detection is sovereign. The harmful diagnostic is not.

What earns its place:

Colonoscopy — from around age 45 (earlier with family history or symptoms), roughly every 10 years if clear. Colorectal cancer is slow-growing and screening-responsive, and the procedure removes precancerous polyps in the same sitting it detects them — a screen that is also a treatment. Stool-based DNA and FIT testing are lower-burden adjuncts for the interval or for those declining scope.

Skin check — periodic dermatological examination for melanoma, more frequent with risk factors (fair skin, history of sunburn, many or atypical moles, family history). Low-harm, high-yield for a cancer whose early excision is usually curative.

Cervical screening — HPV testing (with Pap where indicated) on the standard interval. The mechanism is understood, the target lesion is real and progressive, and the intervention window is wide.

Prostate — PSA read in clinical context, never PSA alone, which carries a high false-positive rate and has driven a documented epidemic of overtreatment. Multiparametric MRI before any biopsy when PSA is elevated or rising, so that indolent disease is not converted into surgical and radiation injury. See Prostate-Health for the detailed protocol.

What does not — mammography.

Mammography is the screening modality that fails its own test, and naming that plainly is part of health sovereignty. The best evidence — the Cochrane review of the randomized trials — finds that for every 2,000 women screened over ten years, roughly one avoids a breast-cancer death, while about ten healthy women are overdiagnosed: cut, irradiated, or given chemotherapy for lesions, much of it ductal carcinoma in situ, that would never have threatened their lives. Around 200 endure the fear and follow-up of a false positive. The test itself delivers ionizing radiation to breast tissue on a repeating schedule, compresses the tissue it images, and loses sensitivity precisely in the dense breasts most at risk. This is not early detection saving lives at the margin; it is a procedure sustained by momentum, litigation-fear, and reimbursement long after the mortality case for it collapsed.

The radiation-free alternatives carry the surveillance without the harm. Breast MRI is the genuine high-sensitivity tool and the correct anchor for high-risk women. Ultrasound serves well for dense tissue and as a first look at a palpable finding. Regular clinical and self-examination costs nothing and misses little that matters at the scale where intervention still helps. Thermography is sometimes offered as a functional adjunct; the evidence for it as a standalone screen is weak, and it should be named as adjunct, never as replacement.

What harms in the act of detecting — PET and the needle biopsy.

Two widely-ordered procedures inflict harm through the very mechanism of detection, and the terrain framework makes their incoherence visible.

The PET scan detects cancer by injecting a radioactive glucose analog (FDG) and watching the fermentative, glucose-hungry cell light up as it takes the tracer in. Read closely, the test is a confession. The entire diagnostic rests on the one fact the treatment paradigm refuses to act on: cancer runs on sugar. Oncology built its most sensitive imaging around the Warburg effect — it finds tumors precisely because they consume glucose faster than any healthy tissue — and then sends the patient to a ward that serves pudding and juice, prescribes no ketogenic protocol, no glucose restriction, and often actively discourages both. A field that stakes its detection on a cancer’s appetite for sugar, and stakes none of its treatment on taking the sugar away, has shown you exactly where its knowledge stops and its profit model begins.

Set beside that, the scan’s material harms are almost secondary: it delivers a meaningful dose of ionizing radiation, usually paired with a CT that adds more, and feeds — however briefly — the very fuel line the metabolic approach works to close. The tracer dose is small; the radiation is not. A single PET-CT can carry a burden equivalent to several years of background exposure, and it is routinely repeated to “monitor progress.” An MRI answers most of the same staging questions with no radiation at all.

Biopsy carries a different structural risk: the procedure that confirms the diagnosis can disturb the tumor’s containment. Passing a needle through a solid tumor can displace malignant cells along the tract, and the mechanical disruption breaches the stromal and fibrin architecture the body uses to wall a tumor off. The conventional literature treats needle-tract seeding as rare and clinically minor — but the mechanism is real and documented across several cancer types, and from the terrain view, where the body’s walling-off of a tumor is an active and defensible function, breaching that containment to obtain a sample is not a neutral act. Where the diagnosis can be reached or strongly supported without it — imaging characterization, circulating tumor DNA, the functional and metabolic markers Monitor already tracks — the non-invasive route is preferred, and biopsy is weighed as the consequential intervention it is rather than a routine formality.

Emerging, radiation-free modalities.

Full-body MRI — whole-body imaging that can detect tumors before symptoms appear, with no ionizing radiation. Still expensive and rarely insured, but increasingly accessible; reasonable annually for high-risk individuals. Its own tradeoff is the incidentaloma — benign findings that trigger further workup — so it is read with the same overdiagnosis discipline applied to everything else here.

Liquid biopsy — circulating tumor DNA tests (such as Grail’s Galleri) screen for many cancer types from a single blood draw, with no radiation and low physical burden. Best as a complement rather than a replacement for the modalities that earn their place above; the technology is maturing quickly and its false-positive profile is still being characterized.

For high-risk genetics (BRCA, Lynch syndrome, etc.):

Genetic testing is worth pursuing for anyone with a strong family history of breast, ovarian, colorectal, or other hereditary cancers. A confirmed mutation changes the surveillance and prevention strategy materially. For BRCA carriers specifically, breast surveillance should anchor on annual MRI — not mammography. This is the point where the radiation argument becomes decisive rather than merely preferable: a BRCA carrier’s DNA-damage repair is already impaired, which makes her the single population for whom repeated diagnostic radiation is most likely to seed the cancer the screen is meant to catch. Risk-reducing salpingo-oophorectomy carries the strongest survival evidence for ovarian-cancer risk in carriers and is typically weighed after childbearing — a real and sometimes decisive option, held as a decision the carrier makes with full information rather than a default handed down. The terrain interventions above still apply; they lower risk even against elevated genetic susceptibility, though they do not replace risk-appropriate surveillance and specialist counsel.

Part II — Treating Active Cancer

Everything above is prevention; everything that follows is treatment. The boundary is real but not a wall. The terrain work of Part I does not stop when a diagnosis arrives — it becomes the ground on which every therapy below either takes hold or fails. A body whose insulin is low, whose inflammation is resolved, whose immune surveillance is intact and whose channels of elimination are open is a body in which enzymes, oxidative agents, repurposed drugs, and metabolic pressure can actually work. Treatment is not a different medicine bolted onto prevention; it is the same architecture, intensified and aimed.

None of what follows is medical advice, and none of it is a solo undertaking. Active cancer is the highest-stakes terrain a person will ever navigate. What is mapped below is the structure of a serious integrative cancer program — the shape of what a sovereign practitioner and an experienced integrative physician build together. Dosing, sequencing, and above all Monitor — bloodwork, imaging, tumor markers, the glucose-ketone index, liver and kidney function — are the safety architecture that makes aggressive natural treatment survivable. Read what follows as the anatomy of that program, not as a recipe to run alone.

The Treatment Architecture — Stand-Alone Modalities, Adjuncts, and the Rotation

A serious natural cancer program is not a single magic bullet but a small number of powerful modalities, maximized and rotated, supported by adjuncts and technologies, all resting on the metabolic-immune terrain. This is the organizing logic of the integrative cancer tradition — Truth Calkins’ synthesis of the Gonzalez enzyme protocol, Seyfried’s metabolic therapy, and the repurposed-drug and oxidative lineages chief among its sources — and it structures the sections that follow.

The architecture runs in four tiers. Stand-alone super-modalities are interventions powerful enough to drive remission in their own right: proteolytic enzyme therapy, the metabolic press-pulse, the high-dose repurposed antiparasitics (ivermectin and mebendazole), the potent oxidative agents (chlorine dioxide, hydrogen peroxide, ozone), and certain targeted supplement combinations (IP6 with inositol, ellagic acid). Adjunctive therapies amplify the stand-alones without carrying a program alone: lactoferrin, AHCC, modified citrus pectin, medicinal mushrooms, high-dose melatonin, Pau d’Arco, acemannan, DMSO. Anti-cancer technologies apply physics rather than chemistry: CellSonic VIPP, Rife frequency, therapeutic hyperthermia, molecular hydrogen, and PEMF. And gentle movement — soft rebounding on a mini-trampoline — drives the lymphatic circulation on which immune surveillance and drainage depend.

The discipline is concentration, not proliferation. The practitioner does not attempt all of it at once. One to three stand-alone modalities, maximized and cycled — pulsing higher doses against short therapeutic fasts to strike the cancer when it is most metabolically exposed — supported by a chosen set of adjuncts and one or two technologies, run consistently and read continuously by Monitor, is the shape of a program that works. Rotation matters because the co-infections and cancer cells that treatment targets are stubborn and adept at developing resistance to any single agent; varying the pressure denies them a stable defense. What defeats cancer is not the perfect single therapy but sustained, intelligent, multi-vector pressure on a terrain that has been made hostile to the disease.

Repurposed Pharmaceuticals — Ivermectin, Mebendazole, and the Benzimidazoles

Among the most significant developments in cancer treatment outside the oncology mainstream is the rediscovery of cheap, off-patent antiparasitic drugs as anticancer agents. Ivermectin, mebendazole, and fenbendazole — molecules developed against worms and parasites, with decades of human and veterinary safety data and long-expired patents — have shown, in a growing body of preclinical research and an expanding clinical case record, the capacity to halt and reverse cancers that conventional treatment had abandoned. That these agents are unpatentable and nearly free is inseparable from the institutional silence around them: a therapy that cannot be monetized draws hostility in proportion to how little it can be sold, exactly as the discernment principle predicts. Harmonism holds them as legitimate stand-alone super-modalities — mechanistically coherent, safe within the dosing discipline described here, and belonging inside a comprehensive terrain program rather than standing as isolated miracle cures.

Ivermectin. The most prominent of the repurposed anticancer drugs. Its proposed mechanisms are several and converge on the fermentative cell: it inhibits the MAPK/ERK proliferation pathway on which a large fraction of cancers depend, disrupts mitochondrial function in cancer cells, induces multiple forms of programmed cell death, and appears to modulate the tumor’s immune evasion. The clinician most associated with its use, Dr. William Makis, reports large numbers of advanced-cancer patients reaching remission on ivermectin combined with mebendazole. Drs. Chetty and Landrito, working explicitly from the MAPK mechanism, report response in roughly seventy percent of cancers — those driven through that pathway — and note that cancers not routed through MAPK do not respond, which is itself the mark of a real rather than a universal mechanism.

Dosing, as the practitioners describe it. Makis has generally used around 1 mg per kilogram of body weight per day, sometimes less for responsive cancers. Chetty and Landrito begin low and titrate slowly upward — to 2 to 2.5 mg per kilogram per day for very advanced disease — letting the body adapt and watching for the one meaningful side effect, dizziness persisting beyond two to three hours, which signals the need to reduce. Ivermectin is fat-dependent for absorption: pills or powder are taken with a meal containing forty grams of fat or more. It must remain in the body for roughly three days after each dose to complete its work, which is why binders and chelators are withheld during ivermectin use — activated charcoal, zeolite, bentonite, chlorella, living silica, and modified citrus pectin will strip the drug before it has finished. Liver enzymes are monitored, though elevation is rare in the reported series.

Sourcing. Internal use requires pure USP-grade ivermectin powder or capsules, free of the toxic fillers in veterinary paste; veterinary horse paste is used only topically, and only for skin cancers. A compounded liposomal nano-emulsion taken sublingually offers superior and faster absorption at lower doses. Source quality is not a detail here — it is the difference between the medicine and a contaminant.

Lactoferrin — the amplifier. Ivermectin is classically paired with lactoferrin, the iron-binding protein described in the supplement stack below. Lactoferrin amplifies ivermectin’s activity and adds its own mechanism: it withdraws iron from the iron-avid tumor microenvironment and induces ferroptosis — the iron-dependent form of programmed cell death — while modulating natural killer activity and cytokine signaling. The ivermectin-plus-lactoferrin pairing is the core of the protocol as Chetty and Landrito run it.

Mebendazole and fenbendazole — the benzimidazole partners. Mebendazole, another repurposed antiparasitic, is the standard companion to ivermectin; Makis combines the two as a matter of course. It acts largely by disrupting the microtubule assembly cancer cells need to divide, and interferes with their glucose uptake, starving the fermentative metabolism the whole protocol targets. Fenbendazole — the veterinary benzimidazole made widely known by the Joe Tippens case — works through the same microtubule mechanism and is used similarly. USP-grade mebendazole powder or capsules, dosed alongside ivermectin under the same binder-avoidance and liver-monitoring discipline, complete the antiparasitic core.

Epistemic status, named honestly. The mechanisms are real and increasingly well-characterized in preclinical work; the human evidence is a large and growing record of clinical cases and practitioner series, not yet the randomized controlled trials the establishment demands before it will look — trials that, for an unpatentable molecule, no one with capital is incentivized to fund. This is a genuine evidentiary asymmetry, and it deserves to be named as one: mechanistically grounded, clinically documented across thousands of cases by the physicians who use it, and unproven by the specific standard whose absence is itself a function of the profit structure. It belongs in a serious cancer program — dosed carefully, paired correctly, and read by Monitor — not as a lottery ticket, and not withheld out of deference to an institution that has declined to study it.

Proteolytic Enzyme Therapy and the Trophoblast Hypothesis

One of the oldest metabolic approaches to active cancer works not by poisoning the tumor but by dissolving its defenses. The rationale traces to an embryological observation made at the turn of the twentieth century. In early pregnancy the trophoblast — the tissue that anchors the embryo to the uterine wall — is invasive, angiogenic, and effectively immortal in exactly the way a tumor is: it burrows into maternal tissue and recruits its own blood supply. Around the seventh week of gestation, as the fetal pancreas begins secreting proteolytic enzymes, the trophoblast abruptly halts its invasion and differentiates into placenta. The inference drawn from this — that pancreatic proteolytic enzymes carry a differentiation and anti-invasive signal, and that a tumor is in some sense a trophoblast that never received the signal to stop — became the seed of a proteolytic enzyme therapy refined across a century of clinical use — from John Beard’s original trophoblastic thesis, through the dentist William Donald Kelley, to Dr. Nicholas Gonzalez, whose individualized pancreatic-enzyme, nutritional, and coffee-enema protocol is its most developed modern expression.

The proposed mechanism is twofold. Proteolytic enzymes taken on an empty stomach, in long fasting windows away from food, circulate systemically and degrade the fibrin coat and stromal scaffolding that shield a tumor from immune recognition; they also act on the tumor’s capacity for unchecked proliferation. High-dose porcine pancreatic enzyme regimens, dosed through the day so the enzymes work on tissue rather than digestion, form the core of the approach.

The epistemic status warrants precision, because this terrain is contested and the claims made for it have often outrun the evidence. Harmonism holds the underlying frame — that restoring the body’s own regulatory and differentiating signals is more coherent than poisoning the whole organism to kill a part of it — as continuous with the metabolic-terrain view of cancer. The mechanistic rationale is real: proteolytic enzymes are fibrinolytic, and the fibrin coat is a genuine mode of immune evasion. A large uncontrolled case record accumulated across three generations of practitioners documents long-term remissions in patients who had exhausted conventional options. Against this stands the one prospective controlled trial, which tested a proteolytic-enzyme-and-detoxification regimen against chemotherapy in pancreatic cancer and found the enzyme-treated patients fared markedly worse — shorter survival, poorer quality of life. Proponents dispute that trial’s patient selection and adherence; the dispute remains unresolved. The honest reading: a mechanistically plausible adjunct with a deep uncontrolled case record and one negative controlled trial — promising, unproven, and not a substitute for the metabolic and immune foundation the rest of this protocol builds. Used at all, it belongs inside a comprehensive terrain approach under experienced oversight, never as a stand-alone gamble.

One physiological caution is structural rather than incidental. When proteolytic enzymes break down tumor tissue quickly, the liver and kidneys must clear the debris; overwhelmed, they can fail — a genuine tumor-lysis risk that arises whenever cancer cells are killed faster than the organs of elimination can keep pace. This is why the historical protocols paired high-dose enzymes with intensive liver and bowel support, including coffee enemas drawn from the older detoxification traditions, and cycled the enzymes rather than running them continuously in the most tumor-burdened patients. Monitor — liver enzymes, renal function, symptom tracking — is not optional here; it is the safety architecture that makes the approach survivable.

Advanced Integrative Technologies

Harmonist practice integrates frontier protocols drawn from the Taoist tonic herbalism lineage and from biophysical medicine. These interventions sit between the validated and the experimental — they carry clinical observation, practitioner experience, and varying degrees of research support. The sovereign practitioner evaluates them as part of a comprehensive approach, not as standalone cures.

CellSonic VIPP

CellSonic VIPP (Very Intense Pressure Pulses) is an extracorporeal shockwave therapy originally developed to shatter kidney stones, evolved into a broader therapeutic platform. The mechanism is biophysical rather than chemical: pressure waves create mechanotransduction (triggering cellular repair), cavitation (physically disrupting calcifications, fibrotic tissue, and tumor masses), neovascularization (stimulating new blood vessel formation), and cellular voltage restoration (resetting membrane potential from the depressed millivolt range characteristic of diseased cells back to the healthy -70 to -90mV range).

In the cancer context, CellSonic VIPP physically disrupts tumor cell membranes, restores cellular voltage in the tumor microenvironment, and triggers immune recognition of previously shielded cancer cells. European clinics integrating CellSonic have reported marked case-level improvements — practitioner observation rather than controlled trial, and named as such. The protocol involves direct treatment of all identified tumor sites plus regular spinal treatments for systemic immune activation.

CellSonic is the most promising biophysical cancer intervention in Harmonist assessment — it operates through physics rather than chemistry, works fast on late-stage tumors, and complements all other interventions. It is not a standalone cure but a powerful component in a comprehensive program. See Cellsonic for the full technical profile.

Rife Frequency Technology

Frequency-based therapy uses specific electromagnetic frequencies to target pathological organisms and dysfunctional cells. The historical lineage traces to Royal Rife’s original research in the 1930s. Modern devices deliver targeted frequencies that resonate with the molecular structure of pathogens and cancer cells, creating mechanical disruption at the cellular level.

The highest-powered Rife devices deliver the strongest therapeutic signal for cancer and serious infections. The treatment involves extended daily sessions with specific frequency programs targeting the cancer type. Rife therapy is most effective as part of a comprehensive protocol — it addresses the pathogenic and cellular dimension but does not fix the metabolic terrain that permitted cancer in the first place.

Therapeutic Hyperthermia

Heat is among the oldest anti-cancer agents and, in principle, one of the best supported. Cancer cells, with their disordered vasculature and fermentative metabolism, dissipate heat poorly and tolerate it far less well than healthy tissue. Sustained temperatures in the fever range (roughly 39–43°C) damage tumor cells directly, provoke immune recognition through heat-shock protein signaling, and amplify the oxidative and metabolic therapies alongside which it is best deployed. Fever is one of the body’s own oldest anti-cancer instruments, and clinical hyperthermia — regional or whole-body — is its established therapeutic expression. The home expression of the same principle uses far-infrared heat to raise core and local tissue temperature across extended sessions; the underlying rationale is sound, though the specific home devices are not validated to the standard of the clinical modality. As with every oxidative and thermal stress, the discipline is dose: enough to stress the tumor, not so much as to deplete the patient.

Hydrogen Therapy

Molecular hydrogen (H₂) is emerging as a significant therapeutic agent, with Japanese research approximately 20 years ahead of Western investigation. Hydrogen acts as a selective antioxidant — it neutralizes the most damaging reactive oxygen species (hydroxyl radical, peroxynitrite) without interfering with the beneficial signaling ROS that the immune system uses. It upregulates the Nrf2 pathway, boosting endogenous antioxidant production (glutathione, SOD).

Protocol: Hydrogen-rich water produced by a high-quality electrolysis generator (using zero-TDS water), consumed fresh within minutes of production (hydrogen dissipates rapidly). Two pitchers in the morning, spaced 3 hours apart. Simultaneous hydrogen gas inhalation through nasal cannula amplifies the effect. In the cancer context, hydrogen therapy provides systemic antioxidant support, reduces inflammation, and supports mitochondrial function — addressing the metabolic terrain while other interventions target the tumor directly.

The Press-Pulse Strategy — Metabolic Therapy in Active Cancer

For active cancer, the metabolic theory yields a specific therapeutic protocol: the press-pulse strategy, formulated by Thomas Seyfried. The logic is direct. Cancer cells depend on glucose and glutamine for fuel. Sustained ketosis (the “press”) restricts glucose system-wide, holding chronic metabolic stress on cancer cells while healthy cells adapt readily to ketone metabolism. Timed fasting (the “pulse”) delivers acute metabolic shocks — 4–5 day water or liquid fasts, or fasting-mimicking cycles — that drive the glucose-ketone index into the 1–3 range where the fermentative cell is most exposed and least able to defend itself. Glutamine restriction extends the same logic to the cancer’s second fuel. The press starves; the pulse strikes; and the metabolic differential the two open is exactly what the body’s own immune surveillance and the oxidative therapies below are positioned to exploit. This is metabolic pressure applied to the terrain, not poison applied to the body.

Hyperbaric oxygen (HBOT) at 2.5–2.75 ATA exploits the same metabolic vulnerability from the oxygen side. Cancer cells dependent on glycolysis cannot handle the increased oxygen tension; healthy cells with functional mitochondria thrive in it. HBOT administered at the end of a short fast — when ketones are elevated and glucose is suppressed — creates a dual metabolic-oxidative assault on cancer cells with negligible cost to healthy tissue. The combination of sustained ketosis, timed fasting, glutamine restriction, and hyperbaric oxygen is the most coherent metabolic cancer therapy currently available — a convergent pressure on the fermentative cell from the fuel side and the oxygen side at once.

This is not an adjunct to conventional oncology. It is medicine on its own ground. Harmonism does not regard cytotoxic chemotherapy and radiation as the legitimate treatment of cancer that a terrain approach politely complements. It regards them as the signature of a captured paradigm — poisoning and burning the whole organism to kill a part of it, sold at enormous profit, defended by an institutional apparatus that suppresses the metabolic and immune understanding on which real recovery depends. The logic refutes itself on its face: an immune-mediated disease of degraded terrain is not healed by an agent that devastates the immune system and degrades the terrain further. What poisons the host cannot restore the host.

The actual medicine is the restoration of the terrain — metabolic, immune, oxidative, detoxificative — the whole architecture this protocol builds. That is not the alternative; it is the path. Where a person is already inside the conventional system, or chooses it under the weight of fear and institutional pressure, the terrain work still holds: it reduces the collateral damage of what is being done to the body and supports whatever capacity for recovery remains. That is harm reduction for those still entangled in the captured order — not an endorsement of the order itself.

Oxygen and Oxidative Therapies

Oxidative therapies — including EBOO (Extracorporeal Blood Oxygenation and Ozonation), hydrogen peroxide protocols, and hyperbaric oxygen — exploit cancer cells’ metabolic vulnerability. Cancer cells, dependent on glycolysis (the Warburg effect), are less able to handle increased oxygen tension than healthy cells with functional mitochondria. EBOO is a particularly advanced modality that oxygenates and ozonates the blood extracorporeally, clearing pathogenic load and restoring oxygen-carrying capacity.

Chlorine dioxide (CDS). Chlorine dioxide solution belongs to the same oxidative family — a selective oxidizer that the integrative cancer tradition, notably Andreas Kalcker’s protocols, places among its stand-alone modalities. Its proposed action is the oxidation of pathogens and the pathogenic load that burdens the cancer terrain, at concentrations healthy tissue tolerates. Here more than anywhere the discernment principle applies with full force: chlorine dioxide is genuinely potent, which is precisely why it is neither trivial nor to be improvised. It demands correct preparation, precise low concentration, timing held away from binders and from vitamin C, and continuous reading by Monitor — and it is contraindicated in G6PD deficiency and alongside other strong oxidizers taken simultaneously. Used outside a proper protocol and without oversight, it can harm. Harmonism holds the oxidative principle as real and chlorine dioxide as a legitimate expression of it; it also holds that potency answers to discipline, and that this agent in particular is run under its established protocol framework and experienced supervision, never by casual self-experiment. The establishment’s campaign against it is partly the reflexive hostility any cheap sovereign agent attracts — and partly a real caution about a powerful oxidizer in untrained hands. Both are true, and Monitor is what separates them.

The Comprehensive Cancer Supplement Stack

The following supplements form the advanced cancer-specific layer, drawn from the tonic herbalism lineage and validated through clinical observation. They are additions to, not replacements for, the foundational anti-inflammatory and immune-support stack described above.

AHCC (Active Hexose Correlated Compound) — a mushroom-derived immunomodulator. Enhances NK cell activity, T-cell function, and dendritic cell maturation. Extensively researched in Japan for cancer adjunctive therapy. Sublingual administration (hold in mouth, dissolve, hold under tongue) improves bioavailability. Daily use in any cancer prevention or treatment protocol.

Modified Citrus Pectin — blocks galectin-3, a protein critically involved in cancer cell adhesion, metastasis, and immune evasion. Also functions as a gentle heavy metal chelator. Particularly well-evidenced for prostate cancer. Two doses daily in cancer protocol.

IP6 (Inositol Hexaphosphate) — with inositol. Enhances NK cell activity, inhibits cancer cell proliferation, and supports healthy cell differentiation. Researched specifically for colon and other cancers. Two to three doses daily in cancer protocol.

Ellagic Acid / Raspberry Seed Powder — Red raspberry seed powder provides concentrated ellagic acid, a polyphenol with potent anti-proliferative, pro-apoptotic, and anti-angiogenic properties. The administration method matters: dry-crush the powder in a mortar and pestle for 5 minutes, take 2 teaspoons in mouth, chew with saliva until liquid, swish for 10–20 minutes, then swallow. This oral absorption method bypasses the poor water solubility of ellagic acid. Ellagic acid also lowers blood sugar, supports stem cell production, and has broad anti-cancer activity. The combination of IP6 + ellagic acid + ketogenic diet forms the core of the supplement-based cancer protocol.

Medicinal mushroom complex — Reishi, turkey tail (PSK/PSP), chaga, maitake, cordyceps, and phellinus. Each contributes distinct immunomodulatory polysaccharides. In combination, they provide broad-spectrum immune potentiation that supports the body’s anti-cancer surveillance.

High-dose melatonin — 20mg at bedtime (far above the 0.5–3mg typical for sleep). At therapeutic doses, melatonin functions as a potent antioxidant and has demonstrated anti-cancer properties in multiple cancer types — anti-proliferative, pro-apoptotic, and anti-angiogenic. This is a cancer-specific intervention, not a sleep supplement.

Aged Garlic Extract — liquid form preferred for bioavailability. Aged garlic extract (AGE) delivers organosulfur compounds (S-allylcysteine, S-allylmercaptocysteine) that have demonstrated anti-proliferative, anti-angiogenic, and immune-potentiating effects across multiple cancer types. AGE is distinct from raw garlic supplementation — the aging process converts unstable allicin into stable, bioavailable compounds with higher therapeutic consistency.

Pau d’Arco (Taheebo) — both as tea and as enema solution. Contains lapachol and beta-lapachone, which have demonstrated anti-cancer and anti-fungal activity. The enema application delivers therapeutic compounds directly to the colonic mucosa — particularly relevant for colorectal cancer prevention and treatment.

Lactoferrin — an iron-binding protein that withdraws iron from the tumor microenvironment. Cancer cells are unusually iron-avid, and iron drives both their proliferation and the hydroxyl-radical chemistry they depend on; sequestering it starves them of a critical substrate and can trigger ferroptosis, an iron-dependent form of programmed cell death. Lactoferrin also modulates natural killer activity and cytokine signaling. Mechanistic and preclinical evidence — a reasonable immune-and-terrain adjunct.

Acemannan — the principal immunomodulatory polysaccharide of aloe. It enhances macrophage and natural killer function and dendritic-cell maturation, and in animal and preliminary human work supports anti-tumor immunity while protecting marrow against cytotoxic insult. Best positioned as immune support — and, for anyone still undergoing conventional cytotoxic treatment, as one of the agents that blunts its collateral damage.

DMSO — an experimental differentiation agent, better supported at the mechanistic than the clinical level. Cell-culture work shows it can suppress certain oncoproteins and push transformed cells back toward a normal phenotype. It is also a potent solvent and carrier, which is both its interest and its caution: it must be diluted before use and it produces a pervasive sulfurous body odor. Frontier tier — promising in principle, thinly evidenced in cancer specifically.

A Note on Discernment

Healing cancer outside the captured paradigm is a wide field, and sovereignty is not credulity — the same discernment that refuses the pharmaceutical industry’s captured epistemology must be turned on the healing field’s own enthusiasms. But the discernment is register, not reflex, and it does not defer to establishment dismissal. Harmonism holds the potent oxidizing antimicrobials — chlorine dioxide and hydrogen peroxide chief among them — as genuinely valuable: effective disinfectants and water treatments, useful topicals, and legitimate expressions of the same oxidative principle that runs through molecular hydrogen, hyperbaric oxygen, and ozone. The establishment’s campaign against them is itself a tell — a cheap, unpatentable, sovereignty-restoring agent draws institutional hostility in direct proportion to how little it can be monetized. What genuine discernment tracks is not whether to use them but how. The oxidative principle is real; the terrain governs the dose. Systemic oxidative therapy is powerful precisely because it is potent, and potency answers to Monitor — delivery route, concentration, timing, and the body’s own measured response, fitted to the person rather than applied by formula.

The same discernment vindicates the repurposed pharmaceuticals. Ivermectin, mebendazole, and fenbendazole are not folk enthusiasms but molecules with characterized mechanisms, deep safety records, and a large clinical case literature — dismissed not because they fail but because they cannot be owned. To refuse them on establishment authority is to mistake the profit model’s silence for scientific judgment; to embrace them uncritically as a cure-all is the opposite error. What earns the place, here as everywhere, is a coherent mechanism, a defensible dose and delivery, an honestly named evidence tier, and the body’s response read by Monitor.

The error that does warrant refusal is the sweeping single-cause cure — “cancer is only a fungus, dissolve it with X” — which collapses a multifactorial disease of terrain into one mechanism and abandons the whole understanding this protocol rests on. A therapy earns its place through a coherent mechanism, a defensible delivery route, an honestly named evidence tier, and the body’s response read by Monitor — never by the confidence of its promoters, and never by the establishment’s disapproval, which on this terrain is as likely to mark a threat to the profit model as a danger to the patient.

The Integration Principle

Cancer prevention is not a separate health project grafted onto life. It is the natural structural consequence of the Wheel of Health rotating in proper alignment: metabolic health sustained and inflammation resolved; immune surveillance kept vigilant while toxic load is drawn down; sleep protected, movement consistent; the body nourished with real food and returned to the rhythms of natural order. The cancer-specific interventions — periodic fasting for autophagy activation, medicinal mushrooms for immune potentiation, sulforaphane for Nrf2 activation, appropriate screening — layer upon a foundation that is already cancer-protective by nature.

The sovereign practitioner does not wait for disease to manifest before restoring the terrain. They build a body that cancer cannot easily inhabit — not through vigilance or fear, but through alignment with Logos. The protocols on this wheel, faithfully executed, create an environment hostile to malignancy — metabolically flexible and immunologically vigilant, its inflammation resolved and its toxic burden cleared. This is not a guarantee — reality is complex and probabilistic — but it is the highest-leverage approach available. And it carries an additional virtue: the same interventions that prevent cancer simultaneously prevent cardiovascular disease, neurodegeneration, metabolic dysfunction, and the entire cascade of chronic inflammatory conditions. Health, at its root, is coherent.

And treatment, in the end, obeys the same law. The therapies of Part II — the enzymes and the metabolic press-pulse, the repurposed drugs and the oxidative agents, the frequencies and the supplement stack — are not a war waged against the body but pressure applied to a terrain, aimed at the fermentative cell and withheld from the healthy one. They work to the precise degree that the terrain of Part I has been restored beneath them. Prevention builds the body cancer cannot inhabit; treatment reclaims the body cancer has entered — and both are the same Wheel, turning toward Logos, the same coherence expressed at two depths of need.

See also: Wheel of Health, Inflammation & Chronic Disease, Purification, Nutrition, Monitor, Supplementation, Recovery, Sleep, Prostate-Health, Biggest Levers, Fat Loss, The First 90 Days